Business
Business Update - Replacement
Business Update - Replacement.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n \n \n The following amendment has been made to the 'Business Update'\n announcement released today, 27 March 2023 at 0700 under RNS No 2296U.\n \n \n \n \n \n The real-world evidence data published in the\n Journal of Primary Care Community Health\n was published in November 2022.\n \n \n \n \n \n All other details remain unchanged. The full amended text is shown below.\n \n \n \n \n \n \n \n \n Renalytix plc \n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Business Update\n \n \n \n LONDON and SALT LAKE CITY, March 27, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business update.\n \n Renalytix has further expanded its insurance coverage base for KidneyIntelX in the Northeast region of the United States with the execution of a coverage contract with EmblemHealth, one of the nation's largest not-for-profit health insurers serving over three million people in the New York Tri-State area. \n \n The EmblemHealth contract and other previously established insurance coverage contracts including Healthfirst, Capital District Physicians Health Plan and Connecticare, build on the comprehensive insurance coverage portfolio necessary to transition to a full commercial payment model for KidneyIntelX prognostic testing in the New York and Connecticut state regions.\n \n As previously disclosed on the Company's November 2022 quarterly earnings call, Renalytix is pursuing a strategy to achieve insurance coverage for KidneyIntelX for a majority of patients in specific United States regions containing large populations living with diabetes and kidney disease. Management believes achieving insurance payment for a majority of the population in KidneyIntelX's indicated use is essential for adoption to proceed. This is particularly important at a primary care or generalist physician level where KidneyIntelX testing is focused, as patients and doctors need to have a clear understanding of test billing practices and the amount of patient financial obligation, if any, once a test is performed.\n \n Renalytix is working with health systems, as well as public and private payers to implement care models informed by KidneyIntelX early risk assessment in patients with diabetes and kidney disease to improve kidney health and red...